To provide a balanced analysis, one must examine Pfizer’s defense against the profiteering accusations. The company and its supporters in the financial and free-market sectors make several compelling points.
First, they argue that the free market works. No government forced Pfizer to develop the vaccine. They pivoted their entire massive corporate structure toward a singular goal at unprecedented speed. The fact that they made a profit is the exact mechanism that incentivized them to work so fast. If you remove the profit motive, they argue, you remove the innovation. Why would a company risk billions if they cannot reap the rewards?
Second, they argue that the price charged to governments was a reflection of the value provided, not the cost of production. In economics, this is known as value-based pricing. How much is it worth to save a life? How much is it worth to open an economy? If a vaccine allows a country to avoid $1 trillion in lockdown damages, paying $20 billion for the vaccine is a spectacular bargain. Pfizer simply charged what the market was willing to bear.
Third, regarding the TRIPS waiver, Pfizer maintained that the bottleneck was not patents, but manufacturing capacity and raw materials. Even if they gave away the patent tomorrow, they argued, other companies couldn’t make it fast enough because the specialized lipid nanoparticles (needed to deliver the mRNA) were in short supply, and the highly skilled labor required to manufacture mRNA vaccines didn’t exist in the quantities needed in the developing world. They positioned themselves as the only entity capable of producing the vaccine at scale, safely and efficiently.
Finally, Pfizer points to their donation programs. The company did, in fact, donate millions of doses to poorer countries. They argue that they acted responsibly and that the logistical challenges of distributing vaccines in the developing world (lack of cold-chain infrastructure, vaccine hesitancy) were the fault of local governments and global health infrastructure, not Pfizer’s pricing.
These arguments hold weight in the boardrooms of Wall Street and the halls of libertarian think tanks. However, they fall flat when applied to the brutal, emotional reality of a global pandemic.
Debunking the Defense—The Moral Vacuum
While Pfizer’s free-market defense is legally sound, it is morally bankrupt when applied to a state of global emergency.
The “innovation incentive” argument fails because it ignores the foundational role of the public sector. If the NIH hadn’t spent decades funding basic mRNA research, if the German government hadn’t funded BioNTech, and if the U.S. taxpayer hadn’t subsidized the clinical trials, Pfizer would have had nothing to innovate with. You cannot claim the reward for a racetrack you didn’t build and a car you didn’t engineer.
The “value-based pricing” argument is equally flawed in a crisis. If your house is on fire, and a firefighter shows up with a hose, the value of that water is infinite. It is the difference between life and death. But if the firefighter charges you your entire life savings to turn on the hose because they recognize its “infinite value,” that is not a market transaction; that is extortion. During a pandemic, the seller holds a monopoly on survival. Pricing survival at a premium is the textbook definition of profiteering.
The argument that “patents aren’t the bottleneck, manufacturing is” is perhaps the most insidious. It is true that building an mRNA factory from scratch takes years. But if Pfizer had issued voluntary licenses and shared its technology in early 2021 (when the waiver was proposed), those factories would be finished now. By refusing to share the IP, Pfizer actively prevented the world from increasing manufacturing capacity. They used the lack of capacity as an excuse to keep the IP, which guaranteed the lack of capacity would persist. It was a circular, self-fulfilling prophecy designed to protect profits.
And the donation argument? Donating a few million doses after you have sold billions to wealthy nations at massive markups is not charity; it is public relations. It is the cost of doing business when you are facing a global PR crisis.
The Real-World Cost—Millions of Unnecessary Deaths
The debate over Pfizer’s profit margins is not just an academic exercise in corporate ethics. It has a body count.
Because Pfizer (and Moderna) refused to waive patents, because they priced out poorer nations, and because they prioritized wealthy bilateral contracts over COVAX, the rollout of vaccines in the Global South was delayed by many months.
In the deadly gap between when the first American received a vaccine and when the first resident of a low-income country received one, the Delta and Omicron variants mutated and swept through unprotected populations.
While it is impossible to attribute every single death during this period directly to Pfizer’s IP policies, epidemiologists and global health organizations have stated clearly that tens of thousands—and potentially hundreds of thousands—of lives could have been saved if vaccine equity had been achieved just a few months earlier. The World Health Organization (WHO) repeatedly warned that “no one is safe until everyone is safe.” Pfizer’s business model actively ensured that everyone was not safe, because “everyone being safe” was bad for the bottom line.
When a family in Uganda buried their father because the hospital ran out of oxygen during the Delta wave, they were collateral damage of a corporate intellectual property strategy. When a mother in Brazil watched her child intubated because the country couldn’t secure enough Paxlovid, she was paying the hidden cost of Pfizer’s tiered pricing model.
This is the true horror of pandemic profiteering. It is not just an abstract transfer of wealth from the public to the private sector; it is a transfer of risk from the private sector to the public. The risk of financial loss was socialized, but the reward of financial gain was privatized. And the ultimate risk—the risk of death and disease—was forced onto the poorest people in the world.
The Aftermath and the Reckoning
As the acute phase of the COVID-19 pandemic subsided, Pfizer found itself in a precarious position. The record revenues were gone, replaced by a massive drop in demand for both vaccines and Paxlovid. In late 2023, Pfizer announced significant cost-cutting measures, layoffs, and a write-down of nearly $1 billion in unsold Paxlovid inventory. The golden goose had stopped laying eggs.
But the political and social damage was done. The pandemic laid bare the ugly underbelly of the pharmaceutical industry in a way no previous crisis had.
The accusations of profiteering have moved from the fringes of activist groups into mainstream political discourse. Lawmakers in the United States and Europe have introduced legislation to limit pharmaceutical patent monopolies during public health emergencies. The concept of a “pandemic treaty” at the WHO is heavily focused on forcing pharmaceutical companies to share technology and data.
Pfizer’s reputation, carefully cultivated over decades, took a severe, perhaps permanent, hit. To a generation of young people who watched the world shut down and then watched pharmaceutical executives become billionaires, Pfizer is no longer a healthcare company; it is a symbol of late-stage capitalism’s failure to serve human needs.
Conclusion: Profit Over People
The story of Pfizer during the COVID-19 pandemic is a tragic paradox. The company possessed a genuine scientific miracle. The Pfizer-BioNTech vaccine, alongside the mRNA technology that underpins it, is one of the greatest achievements in the history of human science. It saved millions of lives and allowed the world to return to normalcy.
But the manner in which that miracle was deployed will be remembered with deep resentment. By doubling their profits, aggressively defending monopolies, pricing out the developing world, and funneling billions back to shareholders through stock buybacks, Pfizer engaged in a systemic, institutionalized form of pandemic profiteering.
They proved that in a crisis, the pharmaceutical industry will not self-regulate. They will not prioritize human life over shareholder value unless forced to do so by governments. The social contract—that corporations owe a duty to the societies that enable their existence—was torn to shreds.
“Adults are banning books, not asking our opinions,” the teens said in a different context, but the sentiment applies here perfectly. The global public was told to trust the science, to take the shot, to lockdown, and to sacrifice. But when it came time to distribute the fruits of that sacrifice, the public’s opinion did not matter. The shareholders’ opinions were the only ones that counted.
Pfizer’s doubled profits will forever be a stain on the legacy of the COVID-19 pandemic. They stand as a grim monument to a dark truth: for Big Pharma, there is no crisis so severe, no death toll so high, that it cannot be leveraged into a quarterly earnings report.
Disclaimer: The content on this blog is for informational purposes only. Author’s opinions are personal and not endorsed. Efforts are made to provide accurate information, but completeness, accuracy, or reliability are not guaranteed. Author is not liable for any loss or damage resulting from the use of this blog. It is recommended to use information on this blog at your own terms.
